Showing 3381-3390 of 10618 results for "".
Improving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
https://reachmd.com/programs/heart-matters/improving-attr-cm-diagnosis-insights-on-heart-failure-phenotypes/35756/Because current guidelines for detecting transthyretin amyloid cardiomyopathy (ATTR-CM) may miss a significant number of patients, a recent study published in the Journal of the American College of Cardiology examined heart failure phenotypes that could constitute overlooked presentations of the disThe Impact of Zero in Rheumatology
https://reachmd.com/programs/medical-industry-feature/the-impact-of-zero-in-rheumatology/32264/Most patients with psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis have symptoms across multiple domains.1-2 In fact, when patients meet certain outcome measures, like ACR50 or ASAS40, they may still have active disease that disrupts everyday life.3-5 And paEvolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
https://reachmd.com/clinical-practice/cardiology/evolocumab-in-patients-without-significant-atherosclerosis-and-with-diabetes-a-cardiology-perspective-on-vesalius-cv/56744/New VESALIUS-CV data show broad cardiovascular benefits of evolocumab in high-risk primary prevention patients with diabetes and no atherosclerosis.Value of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
https://reachmd.com/clinical-practice/cardiology/value-of-earlier-lipid-lowering-therapy-intensification-with-evolocumab-in-high-risk-populations-without-known-significant-ascvd-and-with-diabetes-vesalius-cv-insights/56624/At ACC 2026, Dr. Giugliano discusses an analysis of VESALIUS-CV showing evolocumab reduced MACE even without atherosclerosis.ReachMD on the Road: Exploring the Mutter Museum
https://reachmd.com/programs/clinicians-roundtable/reachmd-on-the-road-exploring-the-mutter-museum/3644/Host Dr. Michael Greenberg takes the show on the road to Philadelphia, where he enjoys a fascinating journey through the Mutter Museum, part of the College of Physicians of Philadephia, the oldest professional society in continuous operation in the United States since 1787. Dr. Greenberg tours the mReachMD on the Road: Exploring the Mutter Museum, Part Two
https://reachmd.com/programs/clinicians-roundtable/reachmd-on-the-road-exploring-the-mutter-museum-part-two/3645/Host Dr. Michael Greenberg continues part two of his disturbingly informative tour of Philadelphia's Mutter Museum, part of the College of Physicians of Philadelphia, the oldest professional society in continuous operation in the United States since 1787. Curator Anna Dhody illuminates many of the mAdvancing Care for Coexisting Psoriasis and Seborrheic Dermatitis
https://reachmd.com/programs/dermconsult/advancing-care-for-coexisting-psoriasis-and-seborrheic-dermatitis/36374/Seborrheic dermatitis and psoriasis often overlap in presentation and location, making accurate diagnosis and effective treatment essential. Hear from Dr. Raj Chovatiya as he shares the latest evidence on non-steroidal therapies, addresses limitations of traditional treatments, and offers practicalApproaches to Utilizing Bone-targeting Therapies in mBC
https://reachmd.com/programs/project-oncology/approaches-to-utilizing-bone-targeting-therapies-in-mbc/15819/How do bone-targeting agents support our metastatic breast cancer patients with bone metastases? Tune in.ReachMD on the Road: Exploring the Mutter Museum, Part Three
https://reachmd.com/programs/clinicians-roundtable/reachmd-on-the-road-exploring-the-mutter-museum-part-three/3646/Host Dr. Michael Greenberg continues part three of his informative tour of Philadelphia's Mutter Museum, part of the College of Physicians of Philadelphia, the oldest professional society in continuous operation in the United States since 1787. Curator Anna Dhody guides this tour of many of the museInvestigating Inebilizumab for Generalized Myasthenia Gravis: Results from MINT
https://reachmd.com/programs/neurofrontiers/investigating-inebilizumab-for-generalized-myasthenia-gravis-results-from-mint/35495/Recently published in The New England Journal of Medicine, the phase 3 Myasthenia Gravis Inebilizumab Trial (MINT) underscores the potential of inebilizumab as a therapeutic option for patients with generalized myasthenia gravis (gMG). This is based on the efficacy findings that inebilizumab signifi